Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986036 PK in hepatic impairment
NCT04634149Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration up to 29 days, Time of maximum observed plasma concentration up to 29 days and 1 more. Started Nov 2020; status: completed.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04634149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634149.